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INTRODUCTION & OBJECTIVES: To identify prostate-specific antigen (PSA) kinetics parameters predictive of (18)F-fluorocholine PET
(18FC PET/CT) features worsening in a cohort of patients with biochemical failure after prostate cancer treatment.
MATERIAL & METHODS: This longitudinal cohort study comprised 103 consecutive patients. All patients underwent two 18FC PET/CT:
one at baseline (PET 1) and one after 6 months (PET 2). Total PSA (tPSA), PSA velocity (vPSA), PSA doubling time (dtPSA), absolute
variation of PSA values between PET2 and PET1 (∆PSA), percentage variation of PSA between the two PSA measurements were
measured from each patients (PSA%). Progression of disease on 18FC PET/CT findings were compared with the PSA kinetics parameters.
The major outcome measures were the disease progression at the PET.
RESULTS: 18FC PET/CT progression between PET1 and PET2 was reported in 64 patients (62.1%), while in 39 cases remained unvaried.
We found that the following PSA kinetic parameters are correlated with worsened 18FC PET/CT findings: ∆PSA >5 ng/mL
(OR=6.44;[95%CI 1.04-39.6]; p=0.04), vPSA >6 ng/mL/month (OR=5.2;[95%CI 0.9-29.8]; p=0.05) and PSAdt 
CONCLUSIONS: PSA kinetics is strictly related to 18FC PET/CT findings. In patients with biochemical relapse, a ∆PSA >5 ng/mL, a PSAdt
6 ng/mL/month are highly predictive of 18FC PET/CT feature worsening, independently from the treatment received.
